Growing community of inventors

Potomac, MD, United States of America

Stacie M Goldberg

Average Co-Inventor Count = 6.00

ph-index = 15

The patent ph-index is calculated by counting the number of publications for which an author has been cited by other authors at least that same number of times.

Forward Citations = 459

Stacie M GoldbergMaria N Jure-Kunkel (15 patents)Stacie M GoldbergAshok Kumar Gupta (15 patents)Stacie M GoldbergJohn P Cogswell (15 patents)Stacie M GoldbergXi-Tao Wang (14 patents)Stacie M GoldbergJon Marc Wigginton (14 patents)Stacie M GoldbergXi Tao Wang (1 patent)Stacie M GoldbergJohn M Wigginton (1 patent)Stacie M GoldbergStacie M Goldberg (15 patents)Maria N Jure-KunkelMaria N Jure-Kunkel (37 patents)Ashok Kumar GuptaAshok Kumar Gupta (19 patents)John P CogswellJohn P Cogswell (17 patents)Xi-Tao WangXi-Tao Wang (20 patents)Jon Marc WiggintonJon Marc Wigginton (19 patents)Xi Tao WangXi Tao Wang (1 patent)John M WiggintonJohn M Wigginton (1 patent)
..
Inventor’s number of patents
..
Strength of working relationships

Company Filing History:

1. Bristol-myers Squibb Compnay (15 from 3,681 patents)


15 patents:

1. 10604575 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

2. 10584170 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

3. 10577423 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

4. 10323092 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

5. 10323093 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

6. 10316090 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

7. 10316091 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

8. 10308714 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

9. 10266594 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

10. 10266595 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

11. 10266596 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

12. 10138299 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

13. 10072082 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

14. 9856320 - Cancer immunotherapy by disrupting PD-1/PD-L1 signaling

15. 9212224 - Antibodies that bind PD-L1 and uses thereof

Please report any incorrect information to support@idiyas.com
idiyas.com
as of
12/6/2025
Loading…